The U.K.’s National Institute for Health & Clinical Excellence (NICE) announced on June 6th that it would be recommending the use of the dexamethasone 0.7g intravitreal implant for the treatment of macular edema due to central retinal vein occlusion (CRVO) and for branch retinal vein occlusion (BRVO) where laser photocoagulation has been ineffective or inappropriate. The implant, marketed as Ozurdex (Allergan, Inc.) completed two 6-month prospective double-masked clinical studies in which 1,267 patients with macular edema due to CRVO or BRVO were randomised to receive either sham or intravitreal injections of the implant.